Lexaria Files S-1 for Resale of 2.76M Shares; DehydraTECH Shows Promise

TL;DR

**LEXX's S-1 for warrant resales is a mixed bag, offering potential capital from exercises but signaling dilution, while DehydraTECH's clinical data in GLP-1s is genuinely promising and warrants a closer look.**

AI Summary

Lexaria Bioscience Corp. (LEXX) is filing an S-1 to register 2,760,000 shares of common stock for resale by selling stockholders, primarily from warrants issued in the September 2025 Offering. The company will not receive proceeds from these resales but anticipates approximately $3,828,333 if all 2,666,667 warrants are exercised at $1.37 per share. LEXX is a biotechnology company focused on its DehydraTECH drug delivery technology, which enhances the bioavailability of APIs for various therapeutic indications including diabetes, weight loss, and hypertension. Recent R&D highlights include human pilot studies showing DehydraTECH-semaglutide and DehydraTECH-tirzepatide producing fewer adverse events compared to Rybelsus and injectable Zepbound, respectively, and DehydraTECH-liraglutide showing comparable functional results to injectable Saxenda. The company also announced positive 8-week interim results from its GLP-1-H24-4 chronic human study on July 28, 2025, showing a 43.5% reduction in gastrointestinal adverse events for DehydraTECH-semaglutide patients. LEXX terminated its ATM facility with JonesTrading on September 19, 2025, after selling only 14,995 shares for gross proceeds of $38,236.00.

Why It Matters

This S-1 filing signals a potential increase in LEXX's public float as selling stockholders prepare to offload up to 2,760,000 shares, which could exert downward pressure on the stock price. For investors, while the company won't directly benefit from these sales, the potential $3.8 million from warrant exercises offers a future capital injection for its ongoing R&D, particularly in the competitive GLP-1/GIP drug delivery space. Employees and customers could see long-term benefits if DehydraTECH's clinical successes, like the 43.5% reduction in GI adverse events for semaglutide, translate into commercial products that challenge established players like Novo Nordisk's Rybelsus and Eli Lilly's Zepbound.

Risk Assessment

Risk Level: high — The filing explicitly states, "Investment in our common stock involves a high degree of risk." The company is a biotechnology firm with no current revenue figures provided, indicating it is pre-commercialization and heavily reliant on R&D success. Furthermore, the S-1 is for the resale of 2,760,000 shares by selling stockholders, meaning the company will not receive any proceeds from these sales, and there's no guarantee the warrants will be exercised, potentially leaving the company without the anticipated $3,828,333.

Analyst Insight

Investors should monitor the volume and price action of LEXX shares closely as selling stockholders begin to resell. While the potential $3.8 million from warrant exercises is positive, the immediate impact of increased supply could be negative. Focus on the upcoming full data analysis for the GLP-1-H24-4 chronic human study and progress on the HYPER-H23-1 IND trial for hypertension, as these clinical milestones are critical for long-term value.

Key Numbers

• 2,760,000 — Shares of Common Stock (Maximum shares offered for resale by selling stockholders)
• $3,828,333 — Aggregate Proceeds (Potential cash proceeds to Lexaria upon full exercise of warrants at $1.37 per share)
• 2,666,667 — Warrants (Number of outstanding warrants issued in September 2025 Offering)
• $1.50 — Share Price (Price per share in the registered direct offering of September 26, 2025)
• $1.37 — Exercise Price (Exercise price per share for the common stock purchase warrants)
• $0.8567 — Common Stock Price (Last reported sales price for LEXX common stock on October 10, 2025)
• 43.5% — Reduction in Adverse Events (Reduction in gastrointestinal adverse events for DehydraTECH-semaglutide patients compared to Rybelsus in GLP-1-H24-4 study interim results)
• 14,995 — Shares Sold (Total shares sold under the terminated ATM facility)
• $38,236.00 — Gross Proceeds (Gross proceeds from shares sold under the terminated ATM facility)
• 126 — Human Volunteers (Number of participants in the GLP-1-H24-4 chronic human study)

Key Players & Entities

• Lexaria Bioscience Corp. (company) — Registrant and biotechnology company
• Richard Christopher (person) — Chief Executive Officer of Lexaria Bioscience Corp.
• H.C. Wainwright & Co., LLC (company) — Placement Agent for the September 2025 Offering
• Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for Lexaria Bioscience Corp.
• FDA (regulator) — Regulatory body for drug approvals
• Rybelsus (company) — Commercial GLP-1 drug used as a control in studies
• Zepbound (company) — Commercial GIP/GLP-1 drug used as a control in studies
• Saxenda (company) — Commercial liraglutide drug used as a control in studies
• JonesTrading Institutional Services LLC (company) — Agent for terminated ATM facility
• Eli Lilly (company) — Manufacturer of Zepbound

FAQ

Key Financial Figures

• $0.001 — 0 shares of our common stock, par value $0.001 per share (the "common stock"), issuabl
• $3,828,333 — ants, for an aggregate of approximately $3,828,333. We cannot predict when and in what amo
• $0.8567 — ed sales price for our common stock was $0.8567 per share and the last reported sales p
• $0.04 — sales price for our listed warrants was $0.04 per listed warrant. Investment in our
• $5,000,000 — ssue and sell, from time to time, up to $5,000,000 of our common stock through the Agent,
• $38,236.00 — e Sales Agreement for gross proceeds of $38,236.00. On September 19, 2025, we terminated t
• $1.50 — 67 shares of common stock at a price of $1.50 per share, and (ii) in a concurrent pri
• $1.37 — f common stock, at an exercise price of $1.37 per share of common stock. Smaller Rep
• $700 million — ock held by non-affiliates is less than $700 million and our annual revenue was less than $1
• $100 million — on and our annual revenue was less than $100 million during the most recently completed fisc
• $250 million — ock held by non-affiliates is less than $250 million or (ii) our annual revenue was less tha
• $2.29 — th a weighted average exercise price of $2.29 per share, under our Equity Incentive P
• $3.75 — th a weighted average exercise price of $3.75 per share. 6 Table of Contents RI

Filing Documents

• lxrp_s1.htm (S-1) — 2367KB
• lxrp_ex51.htm (EX-5.1) — 7KB
• lxrp_ex231.htm (EX-23.1) — 2KB
• lxrp_ex107.htm (EX-FILING FEES) — 37KB
• lxrp_s1img4.jpg (GRAPHIC) — 14KB
• lxrp_s1img3.jpg (GRAPHIC) — 14KB
• lxrp_ex51img1.jpg (GRAPHIC) — 7KB
• 0001640334-25-001839.txt ( ) — 9357KB
• lxrp-20250531.xsd (EX-101.SCH) — 76KB
• lxrp-20250531_lab.xml (EX-101.LAB) — 408KB
• lxrp-20250531_cal.xml (EX-101.CAL) — 51KB
• lxrp-20250531_pre.xml (EX-101.PRE) — 346KB
• lxrp-20250531_def.xml (EX-101.DEF) — 194KB
• lxrp_s1_htm.xml (XML) — 1783KB
• lxrp_ex107_htm.xml (XML) — 7KB

RISK FACTORS

RISK FACTORS 7 SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS 16

USE OF PROCEEDS

USE OF PROCEEDS 16 MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS 17

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 27 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 41 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 52

SECURITY OWNERSHIP OF BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF BENEFICIAL OWNERS AND MANAGEMENT 53

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 54

DESCRIPTION OF SECURITIES TO BE REGISTERED

DESCRIPTION OF SECURITIES TO BE REGISTERED 57 SELLING STOCKHOLDERS 57 PLAN OF DISTRIBUTION 60 LEGAL MATTERS 62 EXPERTS 62 WHERE YOU CAN FIND MORE INFORMATION 62 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 ii Table of Contents ABOUT THIS PROSPECTUS This prospectus relates to the resale by the selling stockholders identified in this prospectus under the caption "Selling Stockholders," from time to time, of up to an aggregate of 2,760,000 shares of common stock. We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the selling stockholders, although we may receive cash from the exercise of the Warrants. You should rely only on the information provided in this prospectus. We have not authorized anyone to provide you with any other information and we take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent changes in our business, financial condition, results of operations and prospects. We are not, and the selling stockholders are not, making offers to sell these securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or solicitation. You should read this prospectus in its entirety before making an investment decision. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any state or jurisdiction where the offer or sale is not permitted. 1 Table of Contents PROSPECTUS SUMMARY This summary

Risk Factors

Risk Factors Investing in our common stock involves significant risks. See "Risk Factors" beginning on page 7 of this prospectus. (1) The number of shares of our common stock to be outstanding after this offering is based on 22,225,846 shares of common stock outstanding as of October 9, 2025, but excludes the following as of such date: 1,484,435 shares of common stock issuable upon exercise of stock options, with a weighted average exercise price of $2.29 per share, under our Equity Incentive Plan (the "Incentive Plan"); and 7,298,171 shares of common stock issuable upon exercise of 7,298,171 outstanding warrants, with a weighted average exercise price of $3.75 per share. 6 Table of Contents

RISK FACTORS

RISK FACTORS An investment in our securities involves a high degree of risk. This prospectus contains a discussion of the risks applicable to an investment in our securities. Prior to deciding about investing in our securities, you should carefully consider the specific factors discussed within this prospectus. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in the offered securities. Risks Related to this Offering The sale or availability for sale of the shares of common stock pursuant to this prospectus may depress the price of our common stock, dilute the interest of our existing stockholders, and encourage short sales by third parties, which could further depress the price of our common stock. To the extent that the selling stockholder sells shares of common stock pursuant to this prospectus, the market price of the shares of common stock may decrease due to the additional selling pressure in the market. In addition, the dilution from exercise of the Warrants may cause stockholders to sell their shares of common stock, which could further contribute to any decline in the price of the common stock. Any downward pressure on the price of the shares of common stock caused by the sale or potential sale of such shares could encourage short sales by third parties. Such sales could place downward pressure on the price of the common stock by increasing the number of shares of common stock being sold, which could further contribute to any decline in the market price of the shares of common stock. Risks Associated with our Business and Industry DehydraTECH-enabled pharmaceutical products may not successfully proceed to commercialization. The advancement of DehydraTECH-enabled pharmaceutical produc